Factors affecting outcome in myasthenia gravis

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Understanding factors influencing MG treatment outcomes is crucial for patient management.

Purpose of the Study:

• To evaluate the long-term effects of demographics, antibody status, and clinical factors on myasthenia gravis treatment outcomes.
• To identify predictors of optimal treatment response in MG patients.

Main Methods:

• Retrospective review of 268 myasthenia gravis patients treated between 1980 and 2014.
• Analysis of demographics, antibody status (acetylcholine receptor, muscle-specific tyrosine kinase), thymus histology, and clinical severity.
• Assessment of outcomes at 2, 5, and 10 years of follow-up using multivariate analysis.

Main Results:

• Optimal outcome was achieved by 64% at 2 years, 73% at 5 years, and 75% at 10 years.
• Factors associated with better outcomes included late onset (after 50), thymectomy, and ocular-only disease.
• Late onset (after age 50) was the only consistent independent predictor of optimal outcome.

Conclusions:

• The prognosis for most myasthenia gravis patients is favorable, irrespective of initial disease severity or antibody status.
• Late-onset myasthenia gravis patients demonstrate a better treatment response.
• Long-term follow-up indicates sustained improvement in a majority of MG patients.